Menlo Park's Intersect ENT Latest Health/Bio IPO To Lower Target
7/15/2014 7:17:24 AM
Nasal implant maker Intersect ENT is the latest in the health and biotech sector to lower its IPO targets, setting price targets to raise up to $74.8 million on Monday. It originally had expected to raise $80 million.
The Menlo Park company led by CEO Lisa Earnhardt now said it plans to sell 5 million shares in a price range of between $11 and $13, which would raise $60 million. The rest would come if it sells an over-allotment that has been set aside for underwiters of the offering.
Help employers find you! Check out all the jobs and post your resume.
comments powered by